Skip to content

OS Therapies OSTX Total Current Liabilities

Total Current Liabilities at other companies

Immunome logo
ImmunomeIMNM
$27.41M-11.0%
CTO
Citius Oncology, Inc.CTOR
$58.81M+18.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$11.6M+107%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$209M+8.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$67.95M+38.1%
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
$11.06M-9.9%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's total current liabilities?
OS Therapies (OSTX) reported total current liabilities of $16.95M in Q1 2026.
How has OS Therapies's total current liabilities changed year-over-year?
OS Therapies's total current liabilities increased by 379.4% year-over-year, from $3.54M to $16.95M.
What is the long-term trend for OS Therapies's total current liabilities?
Over 2 years (2023 to 2025), OS Therapies's total current liabilities has grown at a -31.0% compound annual growth rate (CAGR), from $24.71M to $11.76M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.